US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.430 +0.030 (+2.14%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
From Cellectis Inc.
Via GlobeNewswire
News headline image
Expert Ratings for Cellectis ↗
 
Via Benzinga
News headline image
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
News headline image
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 8, 2023 ↗
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
News headline image
A Preview Of Cellectis's Earnings ↗
 
Via Benzinga
News headline image
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via GlobeNewswire
News headline image
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
News headline image
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Cellectis Announces Launch of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why Is Calyxt (CLXT) Stock Up 140% Today? ↗
Calyxt (CLXT) stock is rocketing higher on Tuesday after the company signed an all-stock merger agreement with Cibus Global. 
Via InvestorPlace
News headline image
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via GlobeNewswire
News headline image
5 Most Expensive Health Care Stocks You Should Worry About ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
News headline image
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via GlobeNewswire
News headline image
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >